387 related articles for article (PubMed ID: 25189519)
1. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
2. Reduction-responsive amphiphilic polymeric prodrugs of camptothecin-polyphosphoester for cancer chemotherapy.
Jin H; Sun M; Shi L; Zhu X; Huang W; Yan D
Biomater Sci; 2018 May; 6(6):1403-1413. PubMed ID: 29595843
[TBL] [Abstract][Full Text] [Related]
3. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
Xu Z; Hou M; Shi X; Gao YE; Xue P; Liu S; Kang Y
Biomater Sci; 2017 Feb; 5(3):444-454. PubMed ID: 28058423
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
5. Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
Fan P; Zhang S; Tian H; Yan N; Dai L; Zhang X; Cheng L; Li C; Li Y; Chen X; Shi G; Yang Y; Wei Y; Deng H
Neoplasma; 2012; 59(6):676-84. PubMed ID: 22862168
[TBL] [Abstract][Full Text] [Related]
6. pH-sensitive prodrug conjugated polydopamine for NIR-triggered synergistic chemo-photothermal therapy.
Zhang H; Sun Y; Huang R; Cang H; Cai Z; Sun B
Eur J Pharm Biopharm; 2018 Jul; 128():260-271. PubMed ID: 29733952
[TBL] [Abstract][Full Text] [Related]
7. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
8. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
9. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment.
Bulbake U; Kommineni N; Ionov M; Bryszewska M; Khan W
Pharm Dev Technol; 2020 Jan; 25(1):9-19. PubMed ID: 30633621
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.
Tang Q; Cao B; Cheng G
Chem Commun (Camb); 2014 Feb; 50(11):1323-5. PubMed ID: 24343195
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
14. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
[TBL] [Abstract][Full Text] [Related]
15. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
16. Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.
Zhang F; Zhu G; Jacobson O; Liu Y; Chen K; Yu G; Ni Q; Fan J; Yang Z; Xu F; Fu X; Wang Z; Ma Y; Niu G; Zhao X; Chen X
ACS Nano; 2017 Sep; 11(9):8838-8848. PubMed ID: 28858467
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y
J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
Sun TM; Du JZ; Yao YD; Mao CQ; Dou S; Huang SY; Zhang PZ; Leong KW; Song EW; Wang J
ACS Nano; 2011 Feb; 5(2):1483-94. PubMed ID: 21204585
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
Xu Z; Zheng W; Yin Z
Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828
[TBL] [Abstract][Full Text] [Related]
20. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
